Axon Enterprise, Inc. (NASDAQ:AXON) Receives $460.33 Consensus PT from Brokerages

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have been given a consensus rating of “Buy” by the thirteen ratings firms that are covering the company, Marketbeat reports. Thirteen analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $488.67.

Several analysts recently weighed in on AXON shares. The Goldman Sachs Group lifted their price objective on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC upped their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Robert W. Baird lifted their price objective on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday. Northland Securities upped their target price on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, JMP Securities lifted their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday, October 31st.

Insider Transactions at Axon Enterprise

In related news, CEO Patrick W. Smith sold 47,314 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $400.07, for a total value of $18,928,911.98. Following the sale, the chief executive officer now owns 2,983,802 shares in the company, valued at $1,193,729,666.14. This represents a 1.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the transaction, the chief financial officer now owns 98,825 shares in the company, valued at approximately $37,449,733.75. This trade represents a 4.20 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 129,739 shares of company stock worth $60,108,622. Insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

Several large investors have recently made changes to their positions in the business. Quent Capital LLC grew its holdings in Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 75 shares during the period. Prestige Wealth Management Group LLC boosted its position in Axon Enterprise by 115.8% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 79 shares in the last quarter. Brooklyn Investment Group purchased a new position in shares of Axon Enterprise during the 3rd quarter valued at approximately $41,000. Finally, Planning Capital Management Corp lifted its stake in shares of Axon Enterprise by 83.3% in the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 55 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 0.3 %

Shares of NASDAQ AXON opened at $687.69 on Friday. Axon Enterprise has a twelve month low of $232.78 and a twelve month high of $698.67. The firm has a market cap of $52.44 billion, a PE ratio of 177.70, a price-to-earnings-growth ratio of 15.13 and a beta of 1.01. The business has a fifty day simple moving average of $516.24 and a two-hundred day simple moving average of $393.77. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.